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“S- and 3H-labeled short, nascent peptides have been extracted from mouse myeloma 
ribosomes after incubation of myeloma fragments with [?S]methionine and r3H]amino 
acids. Edman analysis of these peptides reveals that most of the methionine is present at 
the N terminus but that other N-terminal amino acids are also present. Light chains 
synthesized by the RPC-20 tumor fragments were purified from ribosomes, cell sap 
(released light chain) and the incubation medium (secreted light chain). Ribosome- 
bound light chains were found to possess some N-terminal methionine whereas released 
and secreted light chains did not. Since methionine is not the N-terminal amino acid of 
light (L) chains purified from the urine of tumor-bearing mice, the results indicate that 
methionine initiates L chain biosynthesis in the myeloma. 
Total nascent %-labeled peptides were extracted from myeloma ribosomes and 
fractionated on Sephadex G-50. Edman analysis of chromatographic fractions of varying 
sizes indicated that the percentage of N-terminal methionine decreased with increasing 
chain length. This behavior is expected if methionine serves as an initiator amino acid 
but is removed before completion of the polypeptide chain on the ribosome. 
Recent studies have indicated that me- 
thionine can serve as an initiator amino 
acid in eucaryotic protein synthesis. Thus, 
Jackson, and Hunter (l), using reticulo- 
cyte ribosomes synchronized at the point of 
initiation, have found that the amino-ter- 
minal amino acid of short, unfinished he- 
moglobin chains is methionine, whereas, 
the N-terminal amino acid of longer and 
completed chains is valine. Similarly, Wil- 
son and Dintzis have found that 15% of the 
labeled hemoglobin chains formed by retic- 
ulocytes have the N-terminal sequence 
Met-Val (2). In vitro evidence in favor of 
initiation by methionine has been adduced 
by several laboratories. Housman et al. (3) 
have found that yeast methionyl-tRNA’s 
can be fractionated into two species, one of 
which, when acylated, accepts a formyl 
group from formyl tetrahydrofolate and 
one of which does not. They have further 
shown, using an in vitro protein-synthesiz- 
ing system from rabbit reticulocytes, that 
the formylatable species donates its methi- 
onine exclusively to the amino terminus of 
the hemoglobin chains made in this sys- 
tem, while the nonformylatable species 
supplies internal methionine. Smith and 
Marcker (4) and Brown and Smith (5) have 
obtained similar results using ribosomes 
and methionyl-tRNA’s from ascites tumor 
cells, and similar functions for the methi- 
onyl-tRNA’s have been demonstrated in 
other eucaryotic systems (6). 
The initiator function of methionine 
thus seems well established, yet only a few 
specific eucaryotic proteins have been 
shown to be initiated with methionine. 
These include hemoglobin (7), protamines 
(8), and the viral proteins synthesized un- 
der the direction of the adenovirus genome 
(9). The present study was undertaken to 
determine whether methionine functions 
as an initiator amino acid in the mouse 
plasmacytoma and to further determine 
whether the specific immunoglobulin 
chains synthesized by plasmacytoma sys- 
tems are initiated with methionine. Three 
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plasma cell tumors were used in this 
study, RPC-20, a A chain producer, MOPC- 
41, a K chain producer and MOPC-104E, a 
heavy and light chain producer, the light 
chain of which is identical in structure to 
the A chain of RPC-20 (10, 11). It was of 
particular interest to investigate the initia- 
tion mechanism in tumors RPC-20 and 
MOPC104E since the L chain’ products of 
these tumors have been shown to possess 
amino-terminal L-pyroglutamic acid (10). 
pGlu has been suggested as an initiator 
amino acid in immunoglobulin biosyn- 
thesis (12). 
While this manuscript was in prepara- 
tion, Prasad and Peterkofsky presented ev- 
idence for the initiation of the RPC-20 
light chain synthesis by methionine (13). 
The studies presented below confirm these 
results, extend them to the MOPC-41 and 
MOPC-104E tumors and also provide infor- 
mation regarding the possibility of initia- 
tion by other amino acids in the mouse 
plasma cell tumor. 
MATERIALS AND METHODS 
Plasma cell tumors were maintained in BALB/c 
mice. Fourteen- to twenty-one-day-old tumors were 
excised and finely minced with scissors in Hanks’ 
solution. The fragments were washed in Hanks’ solu- 
tion and were incubated with [“Sl- or 
[SH]methionine and, in some experiments, also with 
a mixture of uniformly labeled F3H]- or “C-labeled 
amino acids. All incubation mixtures contained the 
following components: Packed tumor fragments, 4 
ml; normal rabbit serum, 0.5 ml; [35S]methionine, 10 
&i/ml (final concentration) or 13H]methionine, 25 
$X/ml (final concentration). [“Sl- and 
[SH]methionine incubation mixtures also contained 
the remaining 19 common amino acids (unlabeled) 
at a final concentration of 0.2 pmol/ml. In incuba- 
tions with 13H]- or ‘“C-amino acid mixtures, the 
label was added to give final concentrations of 25 or 
5 &i/ml, respectively, and those amino acids that 
were missing from the labeled mixtures were added 
(unlabeled) to a final concentration of 0.2 pmol/ml 
each. All reaction mixtures were brought to a final 
volume of 10 ml with Hanks’ solution, pH 7.4, forti- 
‘Abbreviations used: DEAE, diethyl amino- 
ethyl; L chain, light chain of immunoglobulin; 
pGlu, bpyroglutamic acid; PTH, phenylthiohydan- 
toin. 
Bed with vitamins and a nitrogen source, and were 
preincubated for 5 min at 37°C without added label. 
The radioactive amino acids were then added and 
the incubations continued for the times indicated in 
the figure and table legends. The incorporation of 
amino acids was stopped by cooling the reaction 
mixtures and by the addition of cycloheximide to a 
final concentration of one mg/ml, followed by sedi- 
mentation of the tumor fragments. 
The fragments were homogenized as described 
previously (141 in two volumes of Buffer 1 (0.05 M 
Tris-HCl, pH 7.6; 0.025 M KCl; 0.005 M MgCl,), 
containing 1 mg/ml of cycloheximide and 1.2% Noni- 
det P-40 (Shell), and a postmitochondrial superna- 
tant fraction was obtained by centrifugation of the 
homogenate at 5OOOg for 10 min at 4°C. The superna- 
tant fluid was layered over a 5-ml cushion of 2 M 
sucrose in Buffer 1 containing 1 mg/ml of cyclohexi- 
mide, and ribosomes were collected by centrifuga- 
tion at 200,OOOg for 18 h in an IEC A-321 rotor. The 
high speed supernatant fluid from this centrifuga- 
tion was removed and saved, the sucrose cushion 
was discarded, and the ribosome pellets were rinsed 
and resuspended in Buffer 1 or 0.1 M sodium acetate, 
pH 5.5. 
Two methods were used to prepare peptidyl tRNA 
from the ribosomes. The first method employed was 
that described by Jackson and Hunter (I) and in- 
volves extraction of the ribosomes with phenol at pH 
5.5. The second method was that of Slabaugh and 
Morris (15). Peptidyl tRNA solutions prepared by 
either method were deacylated by treatment with 
pancreatic ribonuclease and base (1). The solutions 
were then brought to 5% with formic acid, freed of 
insoluble material by centrifugation, and applied to 
a 1.5 x IlO-cm column of Sephadex G-50 or a 1.2 x 
70-cm column of Sephadex G-10, each equilibrated 
with 5% formic acid. Peptides were eluted with 5% 
formic acid and relevant fractions were pooled and 
lyophilized. Edman degradation was preformed as 
described by Konigsberg and Hill (16). 
[3SS]methionine-labeled light chains were pre- 
pared by incubation of tumor fragments for 3-4 h in 
the medium described above and were purified as 
previously described (17). Sodium dodecyl sulfate- 
acrylamide-gel electrophoresis was performed on 
10% acrylamide gels as described by Laemmli (18). 
In some experiments gels were processed as previ- 
ously described for scintillation counting (19). Elec- 
trophoresis of peptides was carried out in pyridine 
acetate, pH 1.9, at 2500 V for 1-2 h. 
[YSlmethionine (11-30 Ci/mmol) and 
[3H]methionine (7.2 Ci/mmol) were obtained from 
Amersham/Searle. Radioactive amino acid mix- 
tures were purchased from New England Nuclear. 
Scintillation counting was performed as previously 
described (14). 
PROTEIN SYNTHESIS IN MYELOMA TUMORS 411 
RESULTS 
Methionine is Found at the N-Terminal 
Position of Nascent Polypeptide Chains 
Obtained from Mouse Myeloma Ribo- 
somes 
Following the procedure of Jackson and 
Hunter (l), short, nascent, [35S]methi- 
onine-labeled peptides were prepared by 
phenol extraction of ribosomes labeled and 
purified as described in Materials and 
Methods. Approximately 10% of the total 
ribosome-bound 35S-peptides were ex- 
tracted by this procedure. The peptide 
material in the aqueous phase from such 
an extraction was subjected to Sephadex 
G-50 chromatography, and a single radio- 
active peak was obtained (data not 
shown). The leading and trailing halves of 
this peak were pooled separately, concen- 
trated and subjected to paper electrophore- 
sis with methionine as a reference. None 
of the peptide fractions (from any of the 
three tumors tested) contained free methi- 
onine (data not shown). Table I shows the 
results of Edman degradation of the 
leading half (fraction A) and trailing half 
(fraction B) from the three tumors. It can 
be seen that 7085% of the methionione in 
fractions A and B from each tumor was 
released in the first round of Edman 
degradation. Since the efficiency of the 
Edman reaction is generally 7585% for 
peptides (161, it can be concluded that 
nearly all methionine in fractions A and B 
is amino terminal. The high level of N- 
terminal methionine found on these small, 
nascent myeloma peptides suggests that 
methionine is the initiator amino acid for 
the synthesis of at least some myeloma 
proteins. These data support the results 
obtained in vitro by Jones and Mach with 
methionyl-tRNA’s (20). 
Specific information on the molecular 
sizes of peptides A and B was obtained by 
chromatography of the phenol-extracted 
aqueous phases on Sephadex G-10. It was 
found that the 93 label of peaks A and B 
eluted in a major peak with a mobility 
slightly greater than that of reduced gluta- 
thione. Skewing toward smaller sizes was 
also observed (data not shown). Thus, 
phenol-extraction procedures appear to 
yield tRNA molecules bearing di- to tetra- 
peptides. 
Is Methionine the Only Initiator Amino 
Acid Used in Myeloma Protein Synthesis? 
To determine whether all proteins in 
mouse myelomas are initiated with methio- 
nine, it was necessary to establish that 
nascent peptides from myeloma ribosomes 
contained only methionine as their N-ter- 
minal amino acid. To this end, doubly la- 
beled incubations were performed with 
MOPC-41 and RPC-20 tumor fragments. 
For these experiments, combinations of 
lY3lmethionione and an [3H]amino acid 
mixture or 13Hlmethionine and a 14[C-] 
amino acid mixture were used. Short, nas- 
cent peptides were prepared by phenol ex- 
traction of labeled ribosomes, and peaks A 
TABLE I 
EDMAN ANALYSIS OF [Y~IMETHIONINE-LABELED PEPTIDES ISOLATED BY PHENOL EXTRACTIONS 
G-50 Initial cpm CPM in ethyl acetate Percent N-terminal 
peak 
MOPC-41 RPC-20 MOPC-104E MOPC-41 RPC-20 MOPC104E MOPC-41 RPC-20 MOPG104E 
A 3920 3080 2320 3290 2150 2040 84.0 70.0 72.3 
B 4040 3280 3400 3290 2450 2952 81.5 74.6 86.8 
a Plasmacytoma ribosomes were prepared from [Vlmethionine incubations as described in Materials and 
Methods and the legend to Fig. 1. The ribosomes were extracted with phenol at pH 5.5 and the aqueous 
extracts were deacylated and chromatographed on Sephadex G-50 as described in Fig. 1. The leading (A) and 
trailing (B) halves of the peptide peak were pooled, concentrated and subjected to Edman degradation (15). 
After cyclization in trifluoroacetic acid, the phenylthiohydantoins were extracted into ethyl acetate. 
Aliquots of the ethyl acetate extracts were counted in a toluene-Omnifluor scintillant. Ethyl acetate- 
extractable a% counts were shown by paper chromatography to be present in PTH-methionine. 
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and B from Sephadex G-50 columns were 
collected together. As a control for this 
experiment, the high speed supernatant 
fraction (S200, presumably containing re- 
leased polypeptide chains which were ex- 
pected to possess little, if any, N-terminal 
methionine) from the ribosome pelleting 
was also prepared. The S2OO’s were sub- 
jected to Edman degradation along with 
the nascent peptides from the correspond- 
ing incubations. The results of these exper- 
iments are shown in Table II. It can be 
seen that 70-85% of the [35S]methionine 
was released after one round of Edman 
degradation. Surprisingly, it was observed 
that l&25% of the tritium counts (amino 
acids other than methionine) were also re- 
leased in the first round for all the tumors 
tested. This result was also obtained with 
peptides from tumor fragments labeled sin- 
gly with methionine or amino acids. These 
data indicate that methionine is not the 
only N-terminal amino acid on short, nas- 
cent myeloma peptides and suggest that 
(ilinitiating methionione is removed very 
rapidly from most nascent polypeptides, 
before they reach lengths of greater than 
four to five amino acids; or (ii)amino acids 
other than methionine participate in initia- 
tion in the myeloma. Low percentages of 
N-terminal methionine and of other amino 
acids were observed on Edman analysis of 
the soluble proteins obtained in the S200 
H. JONES 
fractions (Table II). The biological signifi- 
cance of these latter results is not clear, 
but the values obtained are similar to 
those observed on Edman analysis of those 
nascent myeloma peptides that are ex- 
cluded from Sephadex G-50 (Table III). 
Methionine Is the Initiator Amino Acid for 
Myeloma Immunoglobulin Light Chain 
Biosynthesis 
In view of the data presented above, it 
did not seem possible to demonstrate me- 
thionine initiation of light chain biosyn- 
thesis by direct Edman analysis of mye- 
loma peptides. It was, thus, necessary to 
attempt the purification of the light chains 
synthesized by tumor fragments under the 
conditions described above. To this end, 
RPC-20 fragments were incubated with 
[YS]methionine for 30 min or 3 h. Total 
nascent peptides were isolated from the 
ribosomes by the procedure of Slabaugh 
and Morris (15) after the 30-min incuba- 
tion. The cell sap (S200) and incubation 
medium from the 3-h incubation were pre- 
pared and processed as described in Mate- 
rials and Methods. Labeled light chain 
was purified from the S200 and cell-free 
incubation medium by chromatography on 
DEAE-cellulose (17). Labeled light chain 
protein was isolated from labeled ribo- 
somes by DEAE-cellulose and Sephadex 
G-200 chromatography. Dodecyl sulfate- 
TABLE II 
EDMAN ANALYSIS OF SEPHADEX G-50 PEAKS A AND B AND S2OO’s FROM 
DOUBLY LABELED INCUBATIONS OF PLASMACYTOMA FRAGMENT@ 
Sample Initial cpm x 10m3 Cpm x 10m3 in 
ethyl acetate 
Percent N-terminal 
T3 3H ??I 3H T3 3H 
RPC-20 AB 3.50 7.91 2.60 1.85 74.2 23.4 
RPC-20 S200 321 976 0.52 8.14 0.2 0.8 
MOPC-41 AB 2.20 5.60 1.83 0.84 83.1 15.0 
MOPC-41 S200 465 1180 3.44 7.54 0.7 0.6 
a Plasmacytoma fragments were incubated with radioactive amino acids as described in Materials and 
Methods, and ribosomes were extracted with phenol to prepare nascent peptides. The high speed superna- 
tant fraction resulting from the preparation of the labeled ribosomes was treated for 2 h at 37°C and pH 10 
and freed of amino acids by passage through Sephadex G-25. Edman analysis was performed on the 
combined A and B peptide fractions and on a suitable aliquot of the high speed supernatant fraction. Results 
essentially identical to those presented above were obtained in the incubations containing PHlmethionine 
and W-labeled amino acids. 
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TABLE III 
RESULTS OF EDMAN ANALYSIS OF [?~]METHIONXNE-LABELED PEPTIDES FROM PLASMACYTOMA PEPTIDYL 
tRNA” 
G-50 Initial cpm Cpm in ethyl acetate Percent N-terminal 
peak 
RPC-20 MOPC-41 MOPC- RPC-20 MOPC41MOPC- RPC-20 MOPC41MOPC 
104E 104E 104E 
I 19,800 21,600 8,650 158 234 130 0.8 1.1 1.5 
II 14,400 41,400 6,800 820 1,610 230 5.7 3.9 3.4 
III 2,450 6,150 1,430 415 855 177 16.9 13.9 12.3 
IV 1,050 1,410 880 345 550 410 32.8 39.0 46.5 
V 1,800 1,350 680 905 650 350 50.2 48.1 51.5 
a Fractions from the Sephadex G-50 column were pooled as described in Fig. 3 and concentrated by 
lyophilization. Aliquots of each peak were subjected to Edman degradation as described by Konigsberg and 
HiR (16). 
acrylamide-gel electrophoresis of the ap- 
propriate fractions from these columns in- 
dicated that the major radioactive protein 
in each case had a mobility similar to au- 
thentic light chain and contained at least 
90% of the total radioactivity recovered 
from the gels (data not shown). 
The light chains obtained by this proce- 
dure were subjected to Edman degradation 
with the result that 8.14, 0.65 and 0.23%, 
respectively, of the total incorporated me- 
thionine was N-terminal on ribosome- 
bound, released and secreted light chains. 
These data suggest that at least some ribo- 
some-bound RPC-20 light chains possess 
N-terminal methionine, whereas released 
and secreted chains do not. This result was 
confirmed by the chromatograhic analysis 
of the ethyl acetate extracts following Ed- 
man degradation. Only the extract from 
the analysis of ribosome-bound L chain 
contained PTH-methionine (Fig. 1). Since 
methionine is not the amino-terminal 
amino acid of the RPC-20 light chains iso- 
lated from urine or serum (101, initiating 
methionine must be removed from most L 
chains before they are completed. Addi- 
tional evidence in support of this conten- 
tion is presented below. 
Initiating Methionine is Lost from the 
Growing Polypeptide Chains Before Their 
Completion 
The data presented above and in Table 
II indicate that released and secreted mye- 
loma peptide chains contain little, if any 
N-terminal methionine. It was of interest 
to determine whether the N-terminal me- 
thionine found on short, nascent peptide 
chains was lost after chain completion or 
at some step during chain growth. For this 
purpose, labeled nascent chains were used 
for the preparation of peptidyl tRNA by 
the procedure of Slabaugh and Morris (15). 
Figure 2 depicts the profile of radioactivity 
obtained on chromatography of the RPC- 
20 peptidyl tRNA on DEAE-cellulose. In 
general, 45-60% of the applied radioactiv- 
ity was recovered in peak I from the 
DEAE-cellulose column and 25-35% was 
recovered in peak II. The materal eluting 
in peak I was shown by chromatography 
on Sephadex G-50 to consist mainly of pep- 
tides that were excluded from the Sepha- 
dex column. Whether this material repre- 
sents peptides obtained from peptidyl 
tRNA by deacylation or large peptides 
that stick nonspecifically to the ribosome 
has not been determined. The material in 
peak II is peptidyl tRNA (15). 
Peptides obtained by deacylation of peak 
II from the DEAE-cellulose column were 
separated by gel filtration. The profile of 
such a column is shown in Fig. 3 for RPC- 
20 peptides. Similar profiles were obtained 
for MOPC-41 and MOPC104E peptides. 
Peptides of sizes ranging from 1 or 2 to 
more than 100 amino acids were obtained, 
with the recovery of radioactivity increas- 
ing with increasing peptide chain length. 
Fractions were pooled as indicated in Fig. 
3 and subjected to Edman degradation. 
The results of typical N-terminal analyses 
are shown in Table III for all three tumors 
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met PTH 
FIG. 1. Paper chromatography of the ethyl ace- 
tate-extractable products obtained by Edman degra- 
dation of RPC-20 light chains. Each of the light 
chain fractions described in the text was subjected to 
Edman degradation and the ethyl acetate extracta- 
ble radioactivity was analyzed by ascending paper 
chromatography on Whatman #1 filter paper using 
butanol/acetic acid/water (4:1:5, by volume) as the 
solvent, Authentic PTH-methionine was used as a 
standard. Open circles, light chain from cell sap; 
closed circles, light chain from incubation medium; 
squares, ribosome-bound light chain. 
tested. As one would predict if methionine 
acts as an initiator amino acid in this sys- 
tem, the percentage of the total methio- 
nine in each column cut which was present 
as N-terminal methionine increased from 
about 1% in fraction I (greater than 100 
amino acids) to about 50% in fraction V 
(less than 15 amino acids). 
DISCUSSION 
The data presented above may be sum- 
marized as follows: (i)Methionine is pres- 
ent at the N terminus of short, nascent 
peptides synthesized on mouse plasmacy- 
toma ribosomes; (ii)most methionine in 
these peptides is N terminal, but methio- 
nine is not the only N-terminal amino acid 
present; (iii)light chains purified from RPC- 
20 ribosomes possess N-terminal methio- 
nine whereas light chains from the cell sap 
and secreted light chains do not; (iv)the 
percentage of N-terminal methionine pres- 
ent on nascent myeloma peptides de- 
creases with increasing peptide chain 
length. Although a maximum of only 50% 
FIG. 2. Preparation of peptidyl tRNA by DEAE- 
cellulose chromatography. Peptidyl tRNA was ob- 
tained from [Vllmethionine-labeled ribosomes by 
the procedure of Slabaugh and Morris (15). Four- 
milliliter fractions were collected initially from the 
DEAE-cellulose column, washed with Buffer 2 (8 M 
urea, 0.05 M 2-mercaptoethanol, and 0.1 M sodium 
acetate, pH 5.5) at a flow rate of one ml/mm. At 
fraction 15, the buffer was changed and 2-ml frac- 
tions were collected by elution with Buffer 3 (8 M 
urea, 0.05 M 2-mercaptoethanol, 0.75 M sodium ace- 
tate, pH 5.5). Fifty-microliter aliquots of fractions 
1-14 were counted and 250-ml aliquots were counted 
from fractions 15-40. Fractions 3-10 and 22-31 were 
pooled and denoted DEAE peaks I and II, respec- 
tively. Similar patterns were obtained for peptide 
preparations from tumors MOPC-41 and MOPC- 
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FIG. 3. Fractionation of nascent peptides from RPC-20 peptidyl tRNA on Sephadex G-50. 
DEAE peak II (Fig. 2) was deacylated and the released peptides were chromatographed on 
Sephadex G-50 as described in Materials and Methods. Cytochrome (104 amino acids), insulin 
(51 amino acids), glucagon (29 amino acids) and free methionine were used as molecular weight 
markers. Fractions were pooled as indicated. 
N-terminal methionine was obtained for 
the smallest peptide fraction isolated by 
Sephadex G-50 chromatography of total 
peptides (fraction V of Fig. 31, it should be 
noted that this fraction contained a large 
amount of urea remaining from the 
DEAE-cellulose chromatographic step. In 
control experiments, it was generally ob- 
served that urea interfered with the Ed- 
man analysis, yielding lower than actual 
N-terminal values. Thus, it is possible 
that nearly all the methionine in the frac- 
tion V peptides is N terminal. 
The results presented above provide 
strong evidence for the function of methio- 
nine as an initiator of protein sythesis gen- 
erally in the plasma cell tumor and also 
indicate that methionine specifically initi- 
ates the biosynthesis of the RPC-20 immu- 
noglobulin chain. This latter result has 
also been obtained by Prasad and Peterkof- 
sky (13). The d:?ta presented in the latter 
publication and in the present report are 
consistent with the finding that the RPC- 
20 light chain purified from urine pos- 
sesses N-terminal pGlu. N-terminal methi- 
onine is removed from the immunoglobu- 
lin chains before their secretion by the 
cells. These observations would seem to 
eliminate the possibility that pGlu serves 
to initiate L chain synthesis in tumor 
RPC-20. 
Another observation that argues for the 
function of methionine as an initiator 
amino acid in the plasmacytoma system is 
the observed decrease in N-terminal methi- 
onine content with increasing peptide 
chain length. If one assumes that the 
larger and smaller nascent peptides repre- 
sent the same finished polypeptides, then 
the reduction in N-terminal methionine 
represents either removal of N-terminal 
methionine or a relative increase in inter- 
nal methionine or both. Since the RPC-20, 
MOPC-41 and MOPC-104E light chains 
contain only two internal methionines (10, 
111, it seems very unlikely that a relative 
increase in internal methionine can be 
wholly responsible for the decrease in N- 
terminal methionine with increasing 
chain length which was observed in the 
experiments of Table II. 
Recent studies with purified L chain 
mRNA indicate that the chains are ini- 
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tially synthesized as higher molecular 
weight precursors (21, 22). Indeed it has 
been shown that methionine initiaties the 
synthesis of the precursor in reticulocyte 
lysates primed with myeloma mRNA (21). 
It seems likely that the labeled product 
purified from ribosomes in the present 
studies contains a significant proportion of 
the precursor, since the light chain derived 
therefrom should not possess N-terminal 
methionine (101. Although ribosome- 
bound protein was analyzed by acrylam- 
ide-gel electrophoresis with an L chain 
standard, it is unlikely that the electropho- 
retie procedure used would have allowed 
the separation of the precursor from the 
final L chain. The data do suggest that 
small amounts of precursor accumulate in- 
side the myeloma cells. 
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